- Agile Therapeutics Reports Fourth Quarter & Full Year 2023 Financial Results and Provides Corporate Update
- Agile Therapeutics Announces Delisting from Nasdaq
- Correction - Agile Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 28, 2024
- Agile Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Friday, March 22, 2024
- Agile Therapeutics Completes Pay-off of Debt and Remains Focused on Business Plan Execution
- Agile Therapeutics Announces Exercise of Warrants for $4.8 Million Gross Proceeds
- Agile Therapeutics Announces Extension Granted by Nasdaq Hearings Panel to Regain Compliance with the Stockholders’ Equity Continued Listing Requirement & Provides Performance Update
- The Biden-Harris Administration Announces New Guidance to Enable Expanded Access to All FDA-Approved Contraceptives Without Cost
- Agile Therapeutics Provides Update on Actions Being Taken to Strengthen the Affordable Care Act’s No-Cost Contraceptive Coverage Requirement
- Agile Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
More ▼
Key statistics
As of last trade, Agile Therapeutics Inc (AGRX:PKC) traded at 0.4075, 103.75% above the 52 week low of 0.20 set on Mar 26, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.425 |
---|---|
High | 0.425 |
Low | 0.4075 |
Bid | -- |
Offer | -- |
Previous close | 0.40 |
Average volume | 67.81k |
---|---|
Shares outstanding | 6.86m |
Free float | 6.83m |
P/E (TTM) | -- |
Market cap | 2.74m USD |
EPS (TTM) | -9.84 USD |
Data delayed at least 15 minutes, as of Apr 26 2024 14:56 BST.
More ▼